Browsing by Author "Anzala, Omu"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
    (Vaccine, 2008) Jaoko, Walter; Nakwagala, Frederick N.; Anzala, Omu; Manyonyi, Gloria Omosa; Birungi, Josephine; Nanvubya, Annet; Ogutu, Hilda; Wakasiaka, Sabina; Matu, Lucy; Odada, Jane; Konde, Carol; Mugisha, Emmanuel; Muluubya, Andrew; Kaleebu, Pontiano
    The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-γ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.